Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Dec 23;385(26):2413-2420.
doi: 10.1056/NEJMoa2115624. Epub 2021 Dec 8.

BNT162b2 Vaccine Booster and Mortality Due to Covid-19

Ronen Arbel  1 , Ariel Hammerman  1 , Ruslan Sergienko  1 , Michael Friger  1 , Alon Peretz  1 , Doron Netzer  1 , Shlomit Yaron  1
Affiliations

BNT162b2 Vaccine Booster and Mortality Due to Covid-19

Ronen Arbel et al. N Engl J Med. .

Abstract

Background: The emergence of the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 and the reduced effectiveness over time of the BNT162b2 vaccine (Pfizer-BioNTech) led to a resurgence of coronavirus disease 2019 (Covid-19) cases in populations that had been vaccinated early. On July 30, 2021, the Israeli Ministry of Health approved the use of a third dose of BNT162b2 (booster) to cope with this resurgence. Evidence regarding the effectiveness of the booster in lowering mortality due to Covid-19 is still needed.

Methods: We obtained data for all members of Clalit Health Services who were 50 years of age or older at the start of the study and had received two doses of BNT162b2 at least 5 months earlier. The mortality due to Covid-19 among participants who received the booster during the study period (booster group) was compared with that among participants who did not receive the booster (nonbooster group). A Cox proportional-hazards regression model with time-dependent covariates was used to estimate the association of booster status with death due to Covid-19, with adjustment for sociodemographic factors and coexisting conditions.

Results: A total of 843,208 participants met the eligibility criteria, of whom 758,118 (90%) received the booster during the 54-day study period. Death due to Covid-19 occurred in 65 participants in the booster group (0.16 per 100,000 persons per day) and in 137 participants in the nonbooster group (2.98 per 100,000 persons per day). The adjusted hazard ratio for death due to Covid-19 in the booster group, as compared with the nonbooster group, was 0.10 (95% confidence interval, 0.07 to 0.14; P<0.001).

Conclusions: Participants who received a booster at least 5 months after a second dose of BNT162b2 had 90% lower mortality due to Covid-19 than participants who did not receive a booster.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Assessment for Eligibility.
CHS denotes Clalit Health Services, and SARS-CoV-2 severe acute respiratory syndrome coronavirus 2.
Figure 2
Figure 2. Cumulative Hazard Ratio for Death Due to Covid-19.
The shaded area indicates the 95% confidence interval. Covid-19 denotes coronavirus disease 2019.
See this image and copyright information in PMC

Comment in

References

    1. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021;384:1412-1423. - PMC - PubMed
    1. Daily new confirmed COVID-19 cases per million people. Our World In Data. September 22, 2021. (https://ourworldindata.org/covid-cases?country=IND~USA~GBR~CAN~DEU~FRA~I...).
    1. Sheikh A, McMenamin J, Taylor B, Robertson C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet 2021;397:2461-2462. - PMC - PubMed
    1. Thomas SJ, Moreira ED Jr, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med 2021;385:1761-1773. - PMC - PubMed
    1. Goldberg Y, Mandel M, Bar-On YM, et al. Waning immunity of the BNT162b2 vaccine: a nationwide study from Israel. August 30, 2021. (https://www.medrxiv.org/content/10.1101/2021.08.24.21262423v1). preprint. - PMC - PubMed